MIM
XERS icon

MetLife Investment Management’s Xeris Biopharma Holdings XERS Stock Holding History

MetLife Investment Management’s Portfolio XERS Stock Details XERS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$445K Buy
+76,763
New +$509K ﹤0.01% 1810
2025
Q2 		– Sell
-81,769
Closed -$449K – 2937
2025
Q1 		$449K Sell
81,769
-5,663
-6% -$22.9K ﹤0.01% 1779
2024
Q4 		$296K Buy
87,432
+28,224
+48% +$90.8K ﹤0.01% 2081
2024
Q3 		$169K Sell
59,208
-23,430
-28% -$60.2K ﹤0.01% 2368
2024
Q2 		$186K Buy
82,638
+24,546
+42% +$49.5K ﹤0.01% 2299
2024
Q1 		$128K Sell
58,092
-13,145
-18% -$34K ﹤0.01% 2422
2023
Q4 		$167K Hold
71,237
– – ﹤0.01% 2336
2023
Q3 		$133K Buy
+71,237
New +$163K ﹤0.01% 2438
2023
Q2 		– Sell
-71,237
Closed -$116K – 2996
2023
Q1 		$116K Buy
71,237
+45,408
+176% +$56.8K ﹤0.01% 2488
2022
Q4 		$34.4K Sell
25,829
-45,025
-64% -$63.6K ﹤0.01% 2788
2022
Q3 		$111K Hold
70,854
– – ﹤0.01% 2634
2022
Q2 		$109K Buy
+70,854
New +$150K ﹤0.01% 2674
2020
Q4 		– Sell
-22,612
Closed -$134K – 2319
2020
Q3 		$134K Buy
+22,612
New +$90.4K ﹤0.01% 2078
2019
Q4 		– Sell
-14,041
Closed -$138K – 2328
2019
Q3 		$138K Hold
14,041
– – ﹤0.01% 2151
2019
Q2 		$161K Buy
+14,041
New +$147K ﹤0.01% 2157

Other funds holding XERS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

MetLife Investment Management's XERS Position: Q1 2026 in Review

MetLife Investment Management opened a new position in Xeris Biopharma Holdings (XERS) in Q1 2026: 76,763 shares worth $445K. The stake represents ﹤0.01% of the portfolio and ranks #1810 among its holdings. This is a return to the name: MetLife Investment Management previously reported a position in XERS as recently as Q1 2025.

MetLife Investment Management first reported a position in XERS in Q2 2019 and has held it in 15 quarters since. The position peaked at $449K in Q1 2025. 237 funds tracked by Wall St. Rank hold XERS as of Q1 2026.

  • MetLife Investment Management held 76,763 shares of Xeris Biopharma Holdings worth $445K as of Q1 2026.
  • Xeris Biopharma Holdings was a new MetLife Investment Management position in Q1 2026.
  • Xeris Biopharma Holdings made up ﹤0.01% of MetLife Investment Management's portfolio in Q1 2026, its #1810 holding.
  • MetLife Investment Management first reported a position in Xeris Biopharma Holdings in Q2 2019 and has held it in 15 quarters since.
  • MetLife Investment Management's Xeris Biopharma Holdings position peaked at $449K in Q1 2025.
  • 237 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q1 2026.

Based on MetLife Investment Management's 13F filing for Q1 2026, filed 14 May 2026.